VarmX

Restoring blood coagulation in patients taking Factor Xa Direct Oral Anticoagulants

Leiden, Netherlands · Founded 2016 · $100.7M raised

Headquarters
Leiden
Employees
11–50
Founded
2016
Business Model
B2B
Website
varmx.com
Total Funding
$100.7M
Last Round
$16.5M GrantFeb 2025
Rounds
5

About

VarmX is a clinical-stage biotech company founded in 2016 as a spin-off from Leiden University Medical Center (LUMC), focused on developing a universal bypassing agent to restore blood coagulation in patients taking Factor Xa Direct Oral Anticoagulants (FXa-DOACs). Its lead asset VMX-C001 targets severe bleeding events and surgical bleeding risk in patients on FXa-DOACs, a growing patient population with limited reversal options. The company has completed a €32M Series B financing and is preparing for a global Phase III pivotal trial.

Summary

VarmX is a Biotech company based in Leiden, Netherlands, founded in 2016. It has raised $100.7M in total across 5 rounds, most recently a $16.5M Grant round in Feb 2025. Investors include European Innovation Council Fund, Ysios Capital and Sound Bioventures.

Tech & App Stack

5 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

GrantFeb 2025
$16.5M

Sign up to see all 5 rounds

Seed through Grant — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

VarmX on Indexed.vc
<a href="https://indexed.vc/companies/varmx"><img src="https://indexed.vc/api/badge/company/varmx" alt="VarmX on Indexed.vc" width="260" height="76" /></a>